Amgen (AMGN)

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer’s disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine’s most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system (“CNS”). Oncotelic has developed a proprietary intranasal nose-to-brain (“N2B”) system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and…

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success.

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system (CNS). Oncotelic has developed a proprietary intranasal nose-to-brain (N2B) system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and Lunai Bioworks Inc. (NASDAQ: LNAI).

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), ( Profile ) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and…

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).

They can weather many storms.

Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and increased competition. Management credi...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

Same market, different outcomes. Here's why Apple sent two indexes to record highs while the Dow slipped.

Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to $8.62 billion. The company expect...

Amgen (AMGN) Q1 2026 Earnings Transcript

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $8.62 billion....

Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.

Biotech company Amgen (NASDAQ:AMGN) will be announcing earnings results this Thursday afternoon. Here’s what investors should know. Amgen beat analysts’ reve...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

This once-beaten-down pharma stock remains an intriguing turnaround story.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising c...